Core Insights - The announcement of the Nobel Prize in Physiology or Medicine is expected to ignite a surge in the research and development of Treg cell therapy technologies and innovative drugs [1] Company Summary - Heptares Therapeutics-B (02142) saw its stock price increase by over 8% during trading, with a current price of 16.65 HKD and a trading volume of 62.23 million HKD [1] - The company is developing a next-generation antibody HBM4003 targeting the CTLA-4 pathway, which has shown excellent safety characteristics in clinical studies and has demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - In the CCR8 target area, Heptares Therapeutics has developed the HBM1022 antibody, which is considered a highly promising candidate in its pipeline and may lead to breakthroughs in tumor immunotherapy [1]
和铂医药-B午前涨逾7% 市场关注Treg细胞疗法潜力